+357 96 030922
info@marketpublishers.com

Chronic Obstructive Pulmonary Disease (COPD) Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

https://marketpublishers.com/r/C6353239244FEN.html
Date: September 2025
Pages: 112
Price: US$ 3,200.00 (Single User License)
ID: C6353239244FEN

Abstracts

Chronic Obstructive Pulmonary Disease (COPD) Market Summary

The chronic obstructive pulmonary disease (COPD) market encompasses a diverse portfolio of pharmacotherapies aimed at managing airflow limitation, reducing exacerbations, and improving quality of life in a progressive respiratory condition characterized by persistent respiratory symptoms and structural lung changes, often driven by tobacco smoke exposure, air pollution, and genetic factors like alpha-1 antitrypsin deficiency. Affecting over 380 million people globally, COPD ranks as the third leading cause of death, with exacerbations accounting for 80% of associated healthcare costs through hospitalizations and oxygen dependencies. The market's core features include long-acting bronchodilators for symptom relief, biologics targeting eosinophilic inflammation in severe subsets, and adjunctive therapies like PDE4 inhibitors for hyperinflammation in chronic bronchitis phenotypes. Treatment paradigms emphasize stepwise escalation per GOLD guidelines, starting with short-acting agents for mild disease and progressing to triple fixed-dose inhalers combining LABA/LAMA/ICS for frequent exacerbators, achieving 20-30% reduction in moderate-to-severe events. Innovations spotlight precision medicine via FeNO and blood eosinophil thresholds (>300 cells/?L) to optimize biologic selection, alongside digital inhalers with adherence sensors curbing 50% non-compliance rates. The sector grapples with underdiagnosis—50% of cases undetected—and multimorbidity burdens like cardiovascular overlaps in 40% of patients, yet benefits from real-world evidence demonstrating 15-25% lung function preservation with early intervention. By 2025, the global COPD market is estimated to be valued between USD 4 billion and USD 7 billion,

with a projected compound annual growth rate (CAGR) of 3.5% to 5.5% through 2030. This steady progression is fueled by aging demographics doubling diagnoses in those over 65, air quality deteriorations in urbanizing regions, and payer shifts toward value-based bundles tying reimbursements to exacerbation-free days. The landscape evolves toward inhalation tech advancements like soft-mist inhalers minimizing oropharyngeal deposition, while biosimilars erode originator premiums by 40%, enhancing equity. COPD therapies embody pulmonology's shift from palliative to disease-modifying care, extending median survival by 2-5 years in adherent cohorts, though diagnostic delays averaging 5 years underscore persistent gaps.

Regional Market Trends

The COPD market exhibits heterogeneous regional patterns, influenced by smoking histories, pollution exposures, and spirometry access disparities.

- North America: Foremost with a CAGR of 3.0%–4.5%, this region's maturity stems from robust CDC surveillance and Medicare Advantage plans incentivizing preventives. The United States, the paramount consumer, drives dynamics through Anoro Ellipta's uptake in alpha-1 deficient subgroups, with urban trends favoring biologics like Dupixent for eosinophilic asthma-COPD overlaps; Canada's provincial programs accelerate Spiriva for Indigenous smokers.

- Europe: Envisaged at a CAGR of 2.5%–4.0%, ERS/ATS collaborations and EMA harmonization foster guideline adherence. Germany leads consumption via SHI coverage for Fasenra in severe exacerbators, while the United Kingdom's NICE appraisals prioritize roflumilast for chronic bronchitis; Eastern Europe's post-industrial legacies boost bronchodilator volumes.

- Asia-Pacific: The highest growth at a CAGR of 4.5%–6.0%, biomass fuel and traffic emissions propel incidences. China dominates as the key market, with NMPA approvals spurring generic tiotropium amid 100 million cases, complemented by Japan's JRS emphasis on mepolizumab for elderly non-smokers.

- Latin America: Projecting a CAGR of 3.5%–5.0%, PAHO respiratory pacts and urban clinics advance equity. Brazil emerges prominently, where SUS integrates umeclidinium/vilanterol for biomass-exposed rural cohorts, trends toward affordable LAMA/LABA in Sao Paulo's polluted hubs.

Middle East and Africa (MEA): Modest at a CAGR of 3.0%–4.5%, donor initiatives like GARD mitigate burdens. Saudi Arabia surges via SFDA imports of Dupixent for desert dust sensitivities, while South Africa's NHLS pilots PDE4 inhibitors amid TB-COPD comorbidities.

Type Analysis

The COPD market is segmented by type, each addressing distinct pathophysiological facets with evolutions toward personalized and inhalation-optimized delivery.

Monoclonal Antibodies: This biologic niche grows at a CAGR of 5.0%–7.0%, targeting IL-5 pathways to deplete eosinophils in 20-30% of severe cases, reducing exacerbations by 50% per METREX trial for mepolizumab/Nucala. Benralizumab/Fasenra's single-dose depletion offers quarterly dosing, while Dupixent (dupilumab) blocks IL-4/13 for Th2-high phenotypes; trends emphasize FeNO-guided initiations and combos with LABA/ICS, with pipeline bispecifics eyeing neutrophilic subsets.

Bronchodilators: The foundational category with a CAGR of 3.0%–4.5%, long-acting muscarinic antagonists (LAMAs) like tiotropium/Spiriva relax airways for 24-hour bronchodilation, achieving 150-200ml FEV1 gains in GOLD B-D stages. LABA/LAMA fixed-doses like Anoro Ellipta synergize for dual relaxation, generic revefenacin/Yupelri via nebulization suiting frail; developments include once-daily dry-powder for adherence, biosimilars eroding 30% costs.

PDE4 Inhibitors: Specialized at a CAGR of 3.5%–5.0%, roflumilast/Daliresp curbs cyclic AMP degradation to dampen neutrophil inflammation in chronic bronchitis, slashing exacerbations 15% per REACT; trends pivot to adjuncts with biologics for hyperinflators, mitigating weight loss via dose titration.

Others: Encompassing corticosteroids like hydrocortisone/Cortef and prednisolone/Prelone generics, this supportive cadre advances at a CAGR of 2.5%–4.0%, providing anti-inflammatory bursts for acute flares with 20-30% symptom relief; evolutions spotlight inhaled variants minimizing systemic HPA suppression, mucolytics for viscous sputum in 40% bronchitics.

+357 96 030922
info@marketpublishers.com

Company Profiles

GlaxoSmithKline: Nucala (mepolizumab) anchors biologics with steady revenues from severe eosinophilic COPD, complemented by Anoro Ellipta (umeclidinium/vilanterol) for dual bronchodilation; GSK's respiratory dominance leverages ViiV synergies for HIV-COPD overlaps.

AstraZeneca: Fasenra (benralizumab) and Daliresp (roflumilast) fortify targeted inflammation, with 2024 sales reflecting EU tender wins; AstraZeneca's inhaler tech innovates breath-actuated devices.

Regeneron/Sanofi: Dupixent (dupilumab) extends atopic dermatitis success to eosinophilic COPD, partnering for global commercialization and Phase 3 expansions.

Boehringer Ingelheim: Spiriva (tiotropium bromide) and Atrovent (ipratropium) sustain LAMA leadership, with nebulized options suiting homebound patients.

Viatris: Generic Yupelri (revefenacin) captures nebulized bronchodilator share, inherited Pfizer portfolio emphasizing affordability in U.S. formularies.

Pfizer: Cortef (hydrocortisone) supports corticosteroid niches, legacy from Upjohn in acute management.

Sandoz: Novartis's generics arm propels tiotropium biosimilars, EU-focused for cost containment.

Teva Pharmaceuticals: Generic roflumilast analogs for chronic bronchitis, Israeli R&D eyeing mucolytic combos.

Dr. Reddy's Laboratories: Indian bronchodilator exports flood APAC, 2024 volumes via WHO prequals.

Sun Pharma: LABA generics for secondary prevention.

Industry Value Chain Analysis

The COPD value chain integrates aerosol engineering with pulmonary function monitoring, from small-molecule synthesis to exacerbation forecasting. Upstream research and development employs computational fluid dynamics for inhaler plume geometry, CRISPR models validating IL-5 targets; Phase III per TORCH designs cost USD 300 million, FDA's QIDP expediting biologics. Clinicals harness 6MWD endpoints and CT densitometry for emphysema, EMA's PRIME for orphans. Midstream synthesizes tiotropium's tropane via chiral resolution, HFA propellants in MDIs yielding 10-20% deposition; Indian CMOs scale 200 tons APIs, biosimilars via comparability protocols. Formulation microspheres for dry-powder, pMDIs with spacers. Downstream controlled logistics to pulmonologists, GSK's apps for peak flow. Marketing via ATS congresses, HEOR $50K/QALY via GOLD stages. Support spirometry and oxygen titrations, FAERS for pneumonia. Verticals like Boehringer streamline from API to registries.

Opportunities and Challenges

Opportunities:

Biologic Precision: Eosinophil thresholds unlock 30% severe subsets, $2B TAM in combos.

Inhaler Digitization: Sensors boost adherence 40%, elderly markets.

Emerging Pollution: APAC's 50% rise via air quality pacts.

Biosimilar Affordability: LAMA generics halve costs, LMIC penetration.

Challenges:

Underdiagnosis Delays: 50% missed via spirometry voids.

Exacerbation Heterogeneity: 20% non-responders demand phenotyping.

Generic Pressures: Revenues erode 40%, R&D squeeze.

Multimorbidity: CV overlaps in 40% complicate dosing.

+357 96 030922
info@marketpublishers.com

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

3.1 Research Scope
3.2 Research Sources
  3.2.1 Data Sources
  3.2.2 Assumptions
3.3 Research Method
Chapter Four Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

6.1 Upstream/Suppliers Analysis
6.2 Chronic Obstructive Pulmonary Disease (COPD) Analysis
  6.2.1 Technology Analysis
  6.2.2 Cost Analysis
  6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

7.1 Latest News
7.2 Merger and Acquisition

7.3 Planned/Future Project
7.4 Policy Dynamics

CHAPTER 8 HISTORICAL AND FORECAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET IN NORTH AMERICA (2020-2030)

8.1 Chronic Obstructive Pulmonary Disease (COPD) Market Size
8.2 Chronic Obstructive Pulmonary Disease (COPD) Market by End Use
8.3 Competition by Players/Suppliers
8.4 Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
8.5 Key Countries Analysis
  8.5.1 United States
  8.5.2 Canada
  8.5.3 Mexico

CHAPTER 9 HISTORICAL AND FORECAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET IN SOUTH AMERICA (2020-2030)

9.1 Chronic Obstructive Pulmonary Disease (COPD) Market Size
9.2 Chronic Obstructive Pulmonary Disease (COPD) Market by End Use
9.3 Competition by Players/Suppliers
9.4 Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
9.5 Key Countries Analysis
  9.5.1 Brazil
  9.5.2 Argentina

CHAPTER 10 HISTORICAL AND FORECAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET IN ASIA & PACIFIC (2020-2030)

10.1 Chronic Obstructive Pulmonary Disease (COPD) Market Size
10.2 Chronic Obstructive Pulmonary Disease (COPD) Market by End Use
10.3 Competition by Players/Suppliers
10.4 Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
10.5 Key Countries Analysis
  10.5.1 China
  10.5.2 India
  10.5.3 Japan
  10.5.4 South Korea
  10.5.5 Southeast Asia

10.5.6 Australia

CHAPTER 11 HISTORICAL AND FORECAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET IN EUROPE (2020-2030)

11.1 Chronic Obstructive Pulmonary Disease (COPD) Market Size
11.2 Chronic Obstructive Pulmonary Disease (COPD) Market by End Use
11.3 Competition by Players/Suppliers
11.4 Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia

CHAPTER 12 HISTORICAL AND FORECAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET IN MEA (2020-2030)

12.1 Chronic Obstructive Pulmonary Disease (COPD) Market Size
12.2 Chronic Obstructive Pulmonary Disease (COPD) Market by End Use
12.3 Competition by Players/Suppliers
12.4 Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type

CHAPTER 13 SUMMARY FOR GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET (2020-2025)

13.1 Chronic Obstructive Pulmonary Disease (COPD) Market Size
13.2 Chronic Obstructive Pulmonary Disease (COPD) Market by End Use
13.3 Competition by Players/Suppliers
13.4 Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type

CHAPTER 14 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET FORECAST (2025-2030)

+357 96 030922
info@marketpublishers.com

14.1 Chronic Obstructive Pulmonary Disease (COPD) Market Size Forecast
14.2 Chronic Obstructive Pulmonary Disease (COPD) Application Forecast
14.3 Competition by Players/Suppliers
14.4 Chronic Obstructive Pulmonary Disease (COPD) Type Forecast

CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

15.1 GlaxoSmithKline
  15.1.1 Company Profile
  15.1.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD) Information
  15.1.3 SWOT Analysis of GlaxoSmithKline
  15.1.4 GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)
15.2 AstraZeneca
  15.2.1 Company Profile
  15.2.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD) Information
  15.2.3 SWOT Analysis of AstraZeneca
  15.2.4 AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)
15.3 Regeneron
  15.3.1 Company Profile
  15.3.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD) Information
  15.3.3 SWOT Analysis of Regeneron
  15.3.4 Regeneron Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)
15.4 Sanofi
  15.4.1 Company Profile
  15.4.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD) Information
  15.4.3 SWOT Analysis of Sanofi
  15.4.4 Sanofi Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)
15.5 Boehringer Ingelheim
  15.5.1 Company Profile
  15.5.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD)

Information
15.5.3 SWOT Analysis of Boehringer Ingelheim
15.5.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)
15.6 Viatris
15.6.1 Company Profile
15.6.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD) Information
15.6.3 SWOT Analysis of Viatris
15.6.4 Viatris Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)
15.7 Pfizer
15.7.1 Company Profile
15.7.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD) Information
15.7.3 SWOT Analysis of Pfizer
15.7.4 Pfizer Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)
15.8 Sandoz
15.8.1 Company Profile
15.8.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD) Information
15.8.3 SWOT Analysis of Sandoz
15.8.4 Sandoz Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)
15.9 Teva Pharmaceuticals
15.9.1 Company Profile
15.9.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD) Information
15.9.3 SWOT Analysis of Teva Pharmaceuticals
15.9.4 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)
15.10 Dr. Reddy's Laboratories
15.10.1 Company Profile
15.10.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD) Information
15.10.3 SWOT Analysis of Dr. Reddy's Laboratories
15.10.4 Dr. Reddy's Laboratories Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)

15.11 Sun Pharma
15.11.1 Company Profile
15.11.2 Main Business and Chronic Obstructive Pulmonary Disease (COPD) Information
15.11.3 SWOT Analysis of Sun Pharma
15.11.4 Sun Pharma Chronic Obstructive Pulmonary Disease (COPD) Revenue, Gross Margin and Market Share (2020-2025)
Please ask for sample pages for full companies list

+357 96 030922
info@marketpublishers.com

Tables & Figures

TABLES AND FIGURES
Table Abbreviation and Acronyms
Table Research Scope of Chronic Obstructive Pulmonary Disease (COPD) Report
Table Data Sources of Chronic Obstructive Pulmonary Disease (COPD) Report
Table Major Assumptions of Chronic Obstructive Pulmonary Disease (COPD) Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Chronic Obstructive Pulmonary Disease (COPD) Picture
Table Chronic Obstructive Pulmonary Disease (COPD) Classification
Table Chronic Obstructive Pulmonary Disease (COPD) Applications
Table Drivers of Chronic Obstructive Pulmonary Disease (COPD) Market
Table Restraints of Chronic Obstructive Pulmonary Disease (COPD) Market
Table Opportunities of Chronic Obstructive Pulmonary Disease (COPD) Market
Table Threats of Chronic Obstructive Pulmonary Disease (COPD) Market
Table Raw Materials Suppliers
Table Different Production Methods of Chronic Obstructive Pulmonary Disease (COPD)
Table Cost Structure Analysis of Chronic Obstructive Pulmonary Disease (COPD)
Table Key End Users
Table Latest News of Chronic Obstructive Pulmonary Disease (COPD) Market
Table Merger and Acquisition
Table Planned/Future Project of Chronic Obstructive Pulmonary Disease (COPD) Market
Table Policy of Chronic Obstructive Pulmonary Disease (COPD) Market
Table 2020-2030 North America Chronic Obstructive Pulmonary Disease (COPD) Market Size
Figure 2020-2030 North America Chronic Obstructive Pulmonary Disease (COPD) Market Size and CAGR
Table 2020-2030 North America Chronic Obstructive Pulmonary Disease (COPD) Market Size by Application
Table 2020-2025 North America Chronic Obstructive Pulmonary Disease (COPD) Key Players Revenue
Table 2020-2025 North America Chronic Obstructive Pulmonary Disease (COPD) Key Players Market Share
Table 2020-2030 North America Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
Table 2020-2030 United States Chronic Obstructive Pulmonary Disease (COPD) Market Size

+357 96 030922
info@marketpublishers.com

Table 2020-2030 Canada Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Mexico Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 South America Chronic Obstructive Pulmonary Disease (COPD) Market Size
Figure 2020-2030 South America Chronic Obstructive Pulmonary Disease (COPD) Market Size and CAGR
Table 2020-2030 South America Chronic Obstructive Pulmonary Disease (COPD) Market Size by Application
Table 2020-2025 South America Chronic Obstructive Pulmonary Disease (COPD) Key Players Revenue
Table 2020-2025 South America Chronic Obstructive Pulmonary Disease (COPD) Key Players Market Share
Table 2020-2030 South America Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
Table 2020-2030 Brazil Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Argentina Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Asia & Pacific Chronic Obstructive Pulmonary Disease (COPD) Market Size
Figure 2020-2030 Asia & Pacific Chronic Obstructive Pulmonary Disease (COPD) Market Size and CAGR
Table 2020-2030 Asia & Pacific Chronic Obstructive Pulmonary Disease (COPD) Market Size by Application
Table 2020-2025 Asia & Pacific Chronic Obstructive Pulmonary Disease (COPD) Key Players Revenue
Table 2020-2025 Asia & Pacific Chronic Obstructive Pulmonary Disease (COPD) Key Players Market Share
Table 2020-2030 Asia & Pacific Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
Table 2020-2030 China Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 India Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Japan Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 South Korea Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Southeast Asia Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Australia Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Europe Chronic Obstructive Pulmonary Disease (COPD) Market Size

+357 96 030922
info@marketpublishers.com

Figure 2020-2030 Europe Chronic Obstructive Pulmonary Disease (COPD) Market Size and CAGR
Table 2020-2030 Europe Chronic Obstructive Pulmonary Disease (COPD) Market Size by Application
Table 2020-2025 Europe Chronic Obstructive Pulmonary Disease (COPD) Key Players Revenue
Table 2020-2025 Europe Chronic Obstructive Pulmonary Disease (COPD) Key Players Market Share
Table 2020-2030 Europe Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
Table 2020-2030 Germany Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 France Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Italy Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Spain Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Belgium Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Austria Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Poland Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 Russia Chronic Obstructive Pulmonary Disease (COPD) Market Size
Table 2020-2030 MEA Chronic Obstructive Pulmonary Disease (COPD) Market Size
Figure 2020-2030 MEA Chronic Obstructive Pulmonary Disease (COPD) Market Size and CAGR
Table 2020-2030 MEA Chronic Obstructive Pulmonary Disease (COPD) Market Size by Application
Table 2020-2025 MEA Chronic Obstructive Pulmonary Disease (COPD) Key Players Revenue
Table 2020-2025 MEA Chronic Obstructive Pulmonary Disease (COPD) Key Players Market Share
Table 2020-2030 MEA Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
Table 2020-2025 Global Chronic Obstructive Pulmonary Disease (COPD) Market Size by Region
Table 2020-2025 Global Chronic Obstructive Pulmonary Disease (COPD) Market Size Share by Region
Table 2020-2025 Global Chronic Obstructive Pulmonary Disease (COPD) Market Size

+357 96 030922
info@marketpublishers.com

by Application
Table 2020-2025 Global Chronic Obstructive Pulmonary Disease (COPD) Market Share by Application
Table 2020-2025 Global Chronic Obstructive Pulmonary Disease (COPD) Key Vendors Revenue
Figure 2020-2025 Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Growth Rate
Table 2020-2025 Global Chronic Obstructive Pulmonary Disease (COPD) Key Vendors Market Share
Table 2020-2025 Global Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
Table 2020-2025 Global Chronic Obstructive Pulmonary Disease (COPD) Market Share by Type
Table 2025-2030 Global Chronic Obstructive Pulmonary Disease (COPD) Market Size by Region
Table 2025-2030 Global Chronic Obstructive Pulmonary Disease (COPD) Market Size Share by Region
Table 2025-2030 Global Chronic Obstructive Pulmonary Disease (COPD) Market Size by Application
Table 2025-2030 Global Chronic Obstructive Pulmonary Disease (COPD) Market Share by Application
Table 2025-2030 Global Chronic Obstructive Pulmonary Disease (COPD) Key Vendors Revenue
Figure 2025-2030 Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Growth Rate
Table 2025-2030 Global Chronic Obstructive Pulmonary Disease (COPD) Key Vendors Market Share
Table 2025-2030 Global Chronic Obstructive Pulmonary Disease (COPD) Market Size by Type
Table 2025-2030 Chronic Obstructive Pulmonary Disease (COPD) Global Market Share by Type
Table GlaxoSmithKline Information
Table SWOT Analysis of GlaxoSmithKline
Table 2020-2025 GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Market Share

+357 96 030922
info@marketpublishers.com

Table AstraZeneca Information
Table SWOT Analysis of AstraZeneca
Table 2020-2025 AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Market Share
Table Regeneron Information
Table SWOT Analysis of Regeneron
Table 2020-2025 Regeneron Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 Regeneron Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 Regeneron Chronic Obstructive Pulmonary Disease (COPD) Market Share
Table Sanofi Information
Table SWOT Analysis of Sanofi
Table 2020-2025 Sanofi Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 Sanofi Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 Sanofi Chronic Obstructive Pulmonary Disease (COPD) Market Share
Table Boehringer Ingelheim Information
Table SWOT Analysis of Boehringer Ingelheim
Table 2020-2025 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease (COPD) Market Share
Table Viatris Information
Table SWOT Analysis of Viatris
Table 2020-2025 Viatris Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 Viatris Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 Viatris Chronic Obstructive Pulmonary Disease (COPD) Market

Share
Table Pfizer Information
Table SWOT Analysis of Pfizer
Table 2020-2025 Pfizer Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 Pfizer Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 Pfizer Chronic Obstructive Pulmonary Disease (COPD) Market Share
Table Sandoz Information
Table SWOT Analysis of Sandoz
Table 2020-2025 Sandoz Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 Sandoz Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 Sandoz Chronic Obstructive Pulmonary Disease (COPD) Market Share
Table Teva Pharmaceuticals Information
Table SWOT Analysis of Teva Pharmaceuticals
Table 2020-2025 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Market Share
Table Dr. Reddy's Laboratories Information
Table SWOT Analysis of Dr. Reddy's Laboratories
Table 2020-2025 Dr. Reddy's Laboratories Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 Dr. Reddy's Laboratories Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 Dr. Reddy's Laboratories Chronic Obstructive Pulmonary Disease (COPD) Market Share
Table Sun Pharma Information
Table SWOT Analysis of Sun Pharma
Table 2020-2025 Sun Pharma Chronic Obstructive Pulmonary Disease (COPD) Revenue Gross Profit Margin
Figure 2020-2025 Sun Pharma Chronic Obstructive Pulmonary Disease (COPD) Revenue and Growth Rate
Figure 2020-2025 Sun Pharma Chronic Obstructive Pulmonary Disease (COPD) Market

Share

......

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Chronic Obstructive Pulmonary Disease (COPD) Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

Product link: https://marketpublishers.com/r/C6353239244FEN.html

Price: US$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C6353239244FEN.html